Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 7/20 | 0.45 |
| ▸ | TSPO | P30536 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | VEGFA | P15692 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1690311 | 0.84 | PTGDR2 (0.59) | MEN1KMT2A | |
| SCHEMBL2113204 | 0.81 | ALDH1A1 (0.43) | PDK1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2113926 | 0.80 | TRPM8 (0.39) | PDK1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2111862 | 0.73 | TSPO (0.50) | TSPOLMNALTB4R2MEN1KMT2A | |
| SCHEMBL5764248 | 0.72 | VNN1 (0.53) | LMNACYP3A4NPSR1MEN1KMT2A | |
| SCHEMBL27658652 | 0.70 | IDO1 (0.37) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2110554 | 0.69 | IDO1 (0.39) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9161045 | 0.69 | FABP4 (0.47) | PDK1TSPOLMNACYP1A2CYP3A4 | |
| SCHEMBL1753571 | 0.68 | PTGDR2 (0.57) | MEN1KMT2A | |
| SCHEMBL5762743 | 0.67 | PTGDR2 (0.56) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611091-B1 | Substituted phenylalkanoic acid derivatives and their use for respiratory disease treatment | ASTRAZENECA AB (SE) | 2014-10-29 | — | — | EP | disclosed |
| US-8158820-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-17 | — | — | US | disclosed |
| US-20110166117-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
| CN-100575330-C | Novel compounds | ASTRAZENECA AB | 2009-12-30 | — | — | CN | disclosed |
| US-20060264435-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | US | disclosed |
| CN-1791572-A | Novel compounds | ASTRAZENECA AB (SE) | 2006-06-21 | — | — | CN | disclosed |
| EP-1611091-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004089885-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166117-A1 | Novel Compounds | ADRA2C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR2 | PDK1 517/4885TSPO 844/4885LMNA 2362/4885 |
| US-20060264435-A1 | Novel compounds | ADRA2C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR2 | PDK1 517/4885TSPO 844/4885LMNA 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.